Holy Grail develops energy storage and battery technology that uses electrons to capture carbon dioxide from the atmosphere. It leverages AI and is involved in the research, development, and engineering of various products like batteries, catalysts, and materials datasets which can be used to cross-validate predictions and simulations of experimental data, enabling industrial clients to ensure and benefit from energy efficiency and economy.

Cytera CellWorks, a biotechnology platform, builds machines that automate growing mammalian cells for biotech. Based in London, England, the company was founded by Ignacio Willats and Ali Afshar.

To help hospitals reduce preventable errors and cut down costs in litigation, Scalpel Ltd. is building an end to end patient safety platform. This AI-powered platform checks and verifies the implementation of safety steps during surgery using a combination of computer vision and machine learning technologies. Unlike standard checklists, Scalpel’s solution doesn’t require any human interaction. Sitting in the background in an operating room it automatically monitors the process and provides real-time feedback to detect and prevent errors.

Mission Zero is a DAC startup with patent-pending breakthrough technology and close the carbon cycle.

Thermulon has developed the first building insulation material to satisfy the criteria of fire-safety, performance and price. Designed from the molecular level up, Thermulon deploys the latest advances in chemical and processing technology into an insulation product that enables buildings to be energy efficient without compromising on fire safety.

The Engineering Company aims to trigger the next industrial revolution by building technology that radically accelerates the invention process. The platform allows enables the design industrial hardware on a profoundly deeper complex level in a tenth of the speed. The company intends their platform to power the next 100 years of hardware invention.

Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.

We passionately join cancer patients in their fight for effective, safe, non-toxic cancer treatments that increase quality of life and survival. As a weapon, we are developing viral immunotherapy which has the potential to drastically improve the clinical treatment of solid tumours and their metastases

Rhizocore Technologies produces locally-adapted mycorrhizal fungi to enhance tree planting success.

Concr combines cutting edge machine learning techniques with a deep scientific understanding of tumour progression to accurately predict cancer evolution in response to treatment. This will enable clinicians to adapt treatments proactively, rather than reactively, to prevent treatment resistance and improve treatment efficacy through precision medicine. Concr aims to: • Reduce treatment resistance • Cut the cost of cancer treatment • Enable proactive treatment adaptation • Save lives

Antiverse is a new type of antibody discovery company accelerating drug development. The Antiverse platform exists at the intersection of structural biology, machine learning and medicine to enable breakthroughs to happen more quickly and cost-effectively. Recognized as one of the top biotech startups in the UK, their service is already in use by big pharma. Founded in 2017, Antiverse is dedicated to engineering the future of drug development to change the course of people's lives. The company is headquartered in Cardiff, Wales. For more information, visit antiverse.io.

DeNoize is a smart window technology that transforms any glass facade into a noise-canceling system.